Which has preferable earnings and valuation, DBVT or INDV?

Indivior has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 186.48 -$146.95M -$4.46 N/A Indivior $1.24B 3.49 $210M $1.95 18.17

Is DBVT or INDV more profitable?

Indivior has a net margin of 19.44% compared to DBV Technologies' net margin of -2,895.37%. DBV Technologies' return on equity of -129.88% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -2,895.37% -129.88% -88.84% Indivior 19.44% -219.26% 29.40%

Does the media favor DBVT or INDV?

In the previous week, DBV Technologies had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Indivior. DBV Technologies' average media sentiment score of 0.94 beat Indivior's score of 0.87 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DBVT or MANE?

Veradermics has lower revenue, but higher earnings than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 186.48 -$146.95M -$4.46 N/A Veradermics N/A N/A N/A N/A N/A

Does the media prefer DBVT or MANE?

In the previous week, Veradermics had 5 more articles in the media than DBV Technologies. MarketBeat recorded 8 mentions for Veradermics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.94 beat Veradermics' score of 0.34 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or DBVT?

In the previous week, DBV Technologies had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Amneal Pharmaceuticals. DBV Technologies' average media sentiment score of 0.94 beat Amneal Pharmaceuticals' score of 0.72 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TVTX or DBVT?

In the previous week, Travere Therapeutics had 6 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Travere Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.94 beat Travere Therapeutics' score of 0.59 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DBV Technologies (DBVT) Competitors

$17.76 -0.47 (-2.56%)

Closing price 03:58 PM Eastern

Extended Trading

$17.75 -0.01 (-0.07%)

As of 04:10 PM Eastern

Compare

DBVT vs. INDV, MANE, AMRX, TVTX, and TWST

Should you buy DBV Technologies stock or one of its competitors? MarketBeat compares DBV Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DBV Technologies include Indivior (INDV), Veradermics (MANE), Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does DBV Technologies compare to Indivior?

DBV Technologies (NASDAQ:DBVT) and Indivior (NASDAQ:INDV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, DBV Technologies had 1 more articles in the media than Indivior. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Indivior. DBV Technologies' average media sentiment score of 0.94 beat Indivior's score of 0.87 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Indivior has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Indivior has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A
Indivior	$1.24B	3.49	$210M	$1.95	18.17

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Indivior has a net margin of 19.44% compared to DBV Technologies' net margin of -2,895.37%. DBV Technologies' return on equity of -129.88% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Indivior	19.44%	-219.26%	29.40%

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 173.04%. Indivior has a consensus target price of $39.33, suggesting a potential upside of 11.02%. Given DBV Technologies' higher possible upside, equities research analysts plainly believe DBV Technologies is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Indivior beats DBV Technologies on 9 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Veradermics?

DBV Technologies (NASDAQ:DBVT) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Veradermics has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Veradermics' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 173.04%. Veradermics has a consensus price target of $109.00, suggesting a potential upside of 12.37%. Given DBV Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe DBV Technologies is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Veradermics had 5 more articles in the media than DBV Technologies. MarketBeat recorded 8 mentions for Veradermics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.94 beat Veradermics' score of 0.34 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

DBV Technologies beats Veradermics on 7 of the 12 factors compared between the two stocks.

How does DBV Technologies compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Amneal Pharmaceuticals currently has a consensus price target of $15.17, indicating a potential upside of 17.75%. DBV Technologies has a consensus price target of $48.50, indicating a potential upside of 173.04%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts clearly believe DBV Technologies is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Amneal Pharmaceuticals has a net margin of 4.01% compared to DBV Technologies' net margin of -2,895.37%. DBV Technologies' return on equity of -129.88% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Amneal Pharmaceuticals has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.36	$72.06M	$0.38	33.89
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market.

In the previous week, DBV Technologies had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 3 mentions for DBV Technologies and 2 mentions for Amneal Pharmaceuticals. DBV Technologies' average media sentiment score of 0.94 beat Amneal Pharmaceuticals' score of 0.72 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats DBV Technologies on 9 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Travere Therapeutics presently has a consensus price target of $48.92, suggesting a potential upside of 8.22%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 173.04%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Travere Therapeutics has higher revenue and earnings than DBV Technologies. Travere Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	8.57	-$25.55M	-$0.23	N/A
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A

Travere Therapeutics has a net margin of -4.00% compared to DBV Technologies' net margin of -2,895.37%. Travere Therapeutics' return on equity of -26.16% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-4.00%	-26.16%	-3.71%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

71.7% of DBV Technologies shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Travere Therapeutics had 6 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Travere Therapeutics and 3 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.94 beat Travere Therapeutics' score of 0.59 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Travere Therapeutics beats DBV Technologies on 10 of the 17 factors compared between the two stocks.

How does DBV Technologies compare to Twist Bioscience?

DBV Technologies (NASDAQ:DBVT) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, DBV Technologies had 2 more articles in the media than Twist Bioscience. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.38 beat DBV Technologies' score of 0.94 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
DBV Technologies	Positive
Twist Bioscience	Positive

DBV Technologies has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

Twist Bioscience has a net margin of -19.85% compared to DBV Technologies' net margin of -2,895.37%. Twist Bioscience's return on equity of -26.73% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-2,895.37%	-129.88%	-88.84%
Twist Bioscience	-19.85%	-26.73%	-19.15%

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 173.04%. Twist Bioscience has a consensus target price of $58.00, suggesting a potential downside of 19.81%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Twist Bioscience has higher revenue and earnings than DBV Technologies. Twist Bioscience is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	186.48	-$146.95M	-$4.46	N/A
Twist Bioscience	$376.57M	11.96	-$77.67M	-$1.33	N/A

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Twist Bioscience beats DBV Technologies on 10 of the 17 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DBVT vs. The Competition

Export

Metric	DBV Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.08B	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-3.98	9.91	18.89	22.53
Price / Sales	186.48	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	4.23	6.63	9.84	6.72
Net Income	-$146.95M	$24.20M	$3.57B	$337.19M
7 Day Performance	-3.98%	-3.24%	-1.16%	0.48%
1 Month Performance	-10.60%	0.53%	3.85%	5.07%
1 Year Performance	123.72%	47.24%	27.40%	34.25%

DBV Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DBVT DBV Technologies	2.7302 of 5 stars	$17.76 -2.6%	$48.50 +173.0%	+135.5%	$1.08B	$5.64M	N/A	80	News Coverage
INDV Indivior	3.2458 of 5 stars	$32.99 -5.4%	$39.33 +19.2%	+170.5%	$4.39B	$1.24B	17.46	1,051
MANE Veradermics	N/A	$101.06 -0.9%	$109.00 +7.9%	N/A	$4.26B	N/A	N/A	19	Analyst Forecast Gap Up
AMRX Amneal Pharmaceuticals	3.9972 of 5 stars	$12.58 -2.5%	$15.17 +20.6%	+70.5%	$4.20B	$3.05B	33.50	8,500
TVTX Travere Therapeutics	2.0161 of 5 stars	$42.99 -4.5%	$48.67 +13.2%	+176.7%	$4.19B	$536.20M	N/A	460	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DBVT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DBV Technologies (DBVT) Competitors

DBVT vs. INDV, MANE, AMRX, TVTX, and TWST

How does DBV Technologies compare to Indivior?

Summary

How does DBV Technologies compare to Veradermics?

Summary

How does DBV Technologies compare to Amneal Pharmaceuticals?

Summary

How does DBV Technologies compare to Travere Therapeutics?

Summary

How does DBV Technologies compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DBV Technologies (DBVT) Competitors

DBVT vs. INDV, MANE, AMRX, TVTX, and TWST

How does DBV Technologies compare to Indivior?

Does the media favor DBVT or INDV?

Which has more volatility & risk, DBVT or INDV?

Which has preferable earnings and valuation, DBVT or INDV?

Do institutionals and insiders hold more shares of DBVT or INDV?

Is DBVT or INDV more profitable?

Do analysts rate DBVT or INDV?

Summary

How does DBV Technologies compare to Veradermics?

Is DBVT or MANE more profitable?

Which has stronger valuation and earnings, DBVT or MANE?

Do analysts rate DBVT or MANE?

Does the media prefer DBVT or MANE?

Do institutionals and insiders have more ownership in DBVT or MANE?

Summary

How does DBV Technologies compare to Amneal Pharmaceuticals?

Do analysts recommend AMRX or DBVT?

Is AMRX or DBVT more profitable?

Which has preferable earnings & valuation, AMRX or DBVT?

Which has more risk & volatility, AMRX or DBVT?

Does the media refer more to AMRX or DBVT?

Do institutionals and insiders believe in AMRX or DBVT?

Summary

How does DBV Technologies compare to Travere Therapeutics?

Do analysts rate TVTX or DBVT?

Which has higher valuation and earnings, TVTX or DBVT?

Is TVTX or DBVT more profitable?

Which has more volatility and risk, TVTX or DBVT?

Do institutionals & insiders have more ownership in TVTX or DBVT?

Does the media refer more to TVTX or DBVT?

Summary

How does DBV Technologies compare to Twist Bioscience?

Does the media favor DBVT or TWST?

Which has more volatility and risk, DBVT or TWST?

Is DBVT or TWST more profitable?

Do analysts prefer DBVT or TWST?

Which has stronger valuation and earnings, DBVT or TWST?

Do institutionals and insiders have more ownership in DBVT or TWST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DBVT vs. The Competition

DBV Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools